A Pilot Study: Hypertension, Endothelial Dysfunction and Retinal Microvasculature in Rheumatic Autoimmune Diseases

被引:10
作者
Mahdy, Ahmed [1 ]
Stradner, Martin [2 ]
Roessler, Andreas [1 ]
Brix, Bianca [1 ]
Lackner, Angelika [2 ]
Salon, Adam [1 ]
Goswami, Nandu [1 ]
机构
[1] Med Univ Graz, Otto Loewi Ctr Res Vasc Biol Immun & Inflammat, Physiol Div, Neue Stiftingtalstr 6, A-8010 Graz, Austria
[2] Med Univ Graz, Rheumatol & Immunol Dept, Auenbruggerpl 15, A-8036 Graz, Austria
关键词
endothelial dysfunction; hypertension; ADMA; connective tissue autoimmune diseases; early sign; pulse wave velocity; SYSTEMIC-LUPUS-ERYTHEMATOSUS; PULSE-WAVE VELOCITY; CARDIOVASCULAR RISK-FACTORS; PRIMARY SJOGRENS-SYNDROME; CORONARY-ARTERY-DISEASE; RHEUMATOLOGY/EUROPEAN LEAGUE; ASYMMETRIC DIMETHYLARGININE; CLASSIFICATION CRITERIA; CAROTID ATHEROSCLEROSIS; ENDOGENOUS INHIBITOR;
D O I
10.3390/jcm10184067
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The etiology of autoimmune rheumatic diseases is unknown. Endothelial dysfunction and premature atherosclerosis are commonly seen in these patients. Atherosclerosis is considered one of the main causes of cardiovascular diseases. Hypertension is considered the most important traditional cardiovascular risk. This case-control study aimed to investigate the relationship between autoimmune diseases and cardiovascular risk. Methods: This study was carried out in patients with rheumatoid arthritis, RA (n = 10), primary Sjogren syndrome, PSS (n = 10), and healthy controls (n = 10). Mean blood pressure (MBP), systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse wave velocity (PWV, an indicator of arterial stiffness) were assessed via a Vicorder device. Asymmetric dimethylarginine (ADMA) was measured via ELISA. Retinal photos were taken via a CR-2 retinal camera, and retinal microvasculature analysis was carried out. T-tests were conducted to compare the disease and control groups. ANOVA and ANOVA-ANCOVA were also used for the correction of covariates. Results: A high prevalence of hypertension was seen in RA (80% of cases) and PSS (40% of cases) compared to controls (only 20% of cases). Significant changes were seen in MBP (RA 101 +/- 11 mmHg; PSS 93 +/- 10 mm Hg vs. controls 88 +/- 7 mmHg, p = 0.010), SBP (148 +/- 16 mmHg in RA vs. 135 +/- 16 mmHg in PSS vs. 128 +/- 11 mmHg in control group; p = 0.007), DBP (77 +/- 8 mmHg in RA, 72 +/- 8 mmHg in PSS vs. 67 +/- 6 mmHg in control; p = 0.010 in RA compared to the controls). Patients with PSS showed no significant difference as compared to controls (MBP: p = 0.240, SBP: p = 0.340, DBP: p = 0.190). Increased plasma ADMA was seen in RA (0.45 +/- 0.069 ng/mL) and PSS (0.43 +/- 0.060 ng/mL) patients as compared to controls (0.38 +/- 0.059 ng/mL). ADMA in RA vs. control was statistically significant (p = 0.022). However, no differences were seen in ADMA in PSS vs. controls. PWV and retinal microvasculature did not differ across the three groups. Conclusions: The prevalence of hypertension in our cohort was very high. Similarly, signs of endothelial dysfunction were seen in autoimmune rheumatic diseases. As hypertension and endothelial dysfunction are important contributing risk factors for cardiovascular diseases, the association of hypertension and endothelial dysfunction should be monitored closely in autoimmune diseases.
引用
收藏
页数:14
相关论文
共 85 条
[1]   EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update [J].
Agca, R. ;
Heslinga, S. C. ;
Rollefstad, S. ;
Heslinga, M. ;
McInnes, B. ;
Peters, M. J. L. ;
Kvien, T. K. ;
Dougados, M. ;
Radner, H. ;
Atzeni, F. ;
Primdahl, J. ;
Sodergren, A. ;
Jonsson, S. Wallberg ;
van Rompay, J. ;
Zabalan, C. ;
Pedersen, T. R. ;
Jacobsson, L. ;
de Vlam, K. ;
Gonzalez-Gay, M. A. ;
Semb, A. G. ;
Kitas, G. D. ;
Smulders, Y. M. ;
Szekanecz, Z. ;
Sattar, N. ;
Symmons, D. P. M. ;
Nurmohamed, M. T. .
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (01) :17-28
[2]   Atherosclerotic cardiovascular disease in patients with chronic inflammatory joint disorders [J].
Agca, R. ;
Heslinga, S. C. ;
van Halm, V. P. ;
Nurmohamed, M. T. .
HEART, 2016, 102 (10) :790-795
[3]   2010 Rheumatoid Arthritis Classification Criteria An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative [J].
Aletaha, Daniel ;
Neogi, Tuhina ;
Silman, Alan J. ;
Funovits, Julia ;
Felson, David T. ;
Bingham, Clifton O., III ;
Birnbaum, Neal S. ;
Burmester, Gerd R. ;
Bykerk, Vivian P. ;
Cohen, Marc D. ;
Combe, Bernard ;
Costenbader, Karen H. ;
Dougados, Maxime ;
Emery, Paul ;
Ferraccioli, Gianfranco ;
Hazes, Johanna M. W. ;
Hobbs, Kathryn ;
Huizinga, Tom W. J. ;
Kavanaugh, Arthur ;
Kay, Jonathan ;
Kvien, Tore K. ;
Laing, Timothy ;
Mease, Philip ;
Menard, Henri A. ;
Moreland, Larry W. ;
Naden, Raymond L. ;
Pincus, Theodore ;
Smolen, Josef S. ;
Stanislawska-Biernat, Ewa ;
Symmons, Deborah ;
Tak, Paul P. ;
Upchurch, Katherine S. ;
Vencovsky, Jiri ;
Wolfe, Frederick ;
Hawker, Gillian .
ARTHRITIS AND RHEUMATISM, 2010, 62 (09) :2569-2581
[4]   Cardiovascular Involvement in Autoimmune Diseases [J].
Amaya-Amaya, Jenny ;
Montoya-Sanchez, Laura ;
Rojas-Villarraga, Adriana .
BIOMED RESEARCH INTERNATIONAL, 2014, 2014
[5]  
Atzeni F, 2014, CLIN EXP RHEUMATOL, V32, P361
[6]   Cardiovascular Consequences of Autoimmune Rheumatic Diseases [J].
Atzeni, Fabiola ;
Nucera, Valeria ;
Gerratana, Elisabetta ;
Fiorenza, Alessia ;
Gianturco, Luigi ;
Corda, Marco ;
Sarzi-Puttini, Piercarlo .
CURRENT VASCULAR PHARMACOLOGY, 2020, 18 (06) :566-579
[7]   ARTERIAL STIFFNESS IN RHEUMATOID ARTHRITIS PATIENTS: DO DISEASE ACTIVITY AND DURATION OF ILLNESS MATTER? [J].
Awalia, Awalia ;
Satyadi, Satyadi ;
Wibisono, Sony ;
Soeroso, Joewono .
ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 :1608-1608
[8]   Is chronic inflammation a determinant of blood pressure in the elderly? [J].
Barbieri, M ;
Ferrucci, L ;
Corsi, AM ;
Macchi, C ;
Lauretani, F ;
Bonafè, M ;
Olivieri, F ;
Giovagnetti, S ;
Franceschi, C ;
Paolisso, G .
AMERICAN JOURNAL OF HYPERTENSION, 2003, 16 (07) :537-543
[9]   Asymmetric dimethylarginine, and endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor [J].
Böger, RH .
JOURNAL OF NUTRITION, 2004, 134 (10) :2842S-2847S
[10]  
Brix B, 2020, LYMPHOLOGY, V53, P109